GEN-MKT-18-7897-A
Aug 14, 2018 | Blogs, Clinical | 0 comments
According to the American Clinical Laboratory Association, more than 7 billion clinical lab tests are performed in the U.S. every year. While mass spectrometry represents only a fraction of the clinical applications, there are a growing number of tests where mass spectrometry is becoming the analytical method of choice. This is particularly the case where accuracy is challenged by interference from other compounds, such as toxicology testing, therapeutic drug monitoring, and in the measurement of low-level endogenous steroids.
This trend shift is driven by the analytical specificity of mass spectrometry as well as the advancement of this technology along with the development of new applications. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a particularly powerful, accurate, and robust technique for clinical diagnostics, especially for quantitative analysis of low concentration compounds. When comparing to conventional analytical techniques, the unique capabilities of mass spectrometry makes it is easy to see why mass spectrometry adoption is accelerating and beginning to play a prominent role in more areas of medicine.
As more labs make the move to mass spec, we look at the top five reasons why:
Clinical Mass Spec from SCIEX – Designed for Routine and Advanced DiagnosticsSCIEX In Vitro Diagnostic Medical Devices combine best-in-class mass spec instruments, intuitive software, and preconfigured methods*. Our solutions are fully backed by market leading service, support, and training to help guarantee your long-term success in adopting mass spec in your clinical lab. If you are:
Consider all the factors above, why is your lab waiting to save time, cut costs and support physicians with greater confidence and more accurate results? Learn More About How SCIEX Clinical Diagnostics Solutions Can Transform Your Clinical Lab >
SCIEX Diagnostics products are for in vitro diagnostic use. Product(s) may not be available in all countries. For information on availability, please contact your local representative. All other SCIEX products are for research use only. Not for use in diagnostic procedures.
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
In analytical laboratories, performance is not optional. Whether supporting regulated pharmaceutical workflows, high-throughput CRO operations, clinical reporting, or food and environmental testing, your mass spectrometry and capillary electrophoresis systems are critical to productivity, compliance, and scientific confidence.
Posted by
You must be logged in to post a comment.
Share this post with your network